Antimicrobial Activity of Ceragenins against Vancomycin-Susceptible and -Resistant Enterococcus spp.
-
Published:2023-11-23
Issue:12
Volume:16
Page:1643
-
ISSN:1424-8247
-
Container-title:Pharmaceuticals
-
language:en
-
Short-container-title:Pharmaceuticals
Author:
Hacioglu Mayram1, Yilmaz Fatima Nur1ORCID, Oyardi Ozlem2ORCID, Bozkurt Guzel Cagla1, Inan Nese3, Savage Paul B.4ORCID, Dosler Sibel1
Affiliation:
1. Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Istanbul University, Istanbul 34116, Turkey 2. Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Gazi University, Ankara 06330, Turkey 3. Medical Microbiology Laboratory, Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, University of Health Sciences Ankara, Ankara 06200, Turkey 4. Department of Chemistry and Biochemistry, Brigham Young University, Provo, UT 84602, USA
Abstract
Ceragenins (CSAs) are a new class of antimicrobial agents designed to mimic the activities of endogenous antimicrobial peptides. In this study, the antibacterial activities of various ceragenins (CSA-13, CSA-44, CSA-90, CSA-131, CSA-138, CSA-142, and CSA-192), linezolid, and daptomycin were assessed against 50 non-repeated Enterococcus spp. (17 of them vancomycin-resistant Enterococcus-VRE) isolated from various clinical specimens. Among the ceragenins evaluated, the MIC50 and MIC90 values of CSA-44 and CSA-192 were the lowest (2 and 4 μg/mL, respectively), and further studies were continued with these two ceragenins. Potential interactions between CSA-44 or CSA-192 and linezolid were tested and synergistic interactions were seen with the CSA-192-linezolid combination against three Enterococcus spp., one of them VRE. The effects of CSA-44 and CSA-192 on the MIC values of vancomycin were also investigated, and the largest MIC change was seen in the vancomycin-CSA-192 combination. The in vivo effects of CSA-44 and CSA-192 were evaluated in a Caenorhabditis elegans model system. Compared to no treatment, increased survival was observed with C. elegans when treated with ceragenins. In conclusion, CSA-44 and CSA-192 appear to be good candidates (alone or in combination) for the treatment of enterococcal infections, including those from VRE.
Funder
Health Institutes of Türkiye
Subject
Drug Discovery,Pharmaceutical Science,Molecular Medicine
Reference36 articles.
1. Gilmore, M.S., Clewell, D.B., Ike, Y., and Shankar, N. (2014). Enterococci: From Commensals to Leading Causes of Drug Resistant Infection, Massachusetts Eye and Ear Infirmary. 2. The Enterococcus: A model of adaptability to its environment;Rice;Clin. Microbiol. Rev.,2019 3. Selleck, E.M., Van Tyne, D., and Gilmore, M.S. (2019). Pathogenicity of enterococci. Microbiol. Spectr., 7. 4. Codelia-Anjum, A., Lerner, L.B., Elterman, D., Zorn, K.C., Bhojani, N., and Chughtai, B. (2023). Enterococcal Urinary Tract Infections: A Review of the Pathogenicity, Epidemiology, and Treatment. Antibiotics, 12. 5. Resistance in Vancomycin-Resistant Enterococci;Miller;Infect. Dis. Clin. N. Am.,2020
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|